Get notified when PURR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Standing Risk Factors

  • Going Concern (unchanged) — Sonnet BioTherapeutics disclosed substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows since inception, and cash on hand of $5.1 million projected to fund operations only into February 2026.
  • Cryptocurrency Treasury Strategy (unchanged) — Filing discloses a named Bitcoin treasury/financing strategy (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material.
NASDAQ: PURR Hyperliquid Strategies Inc S-1/A

PURR S-1/A adds Sonnet biotech subsidiary with going-concern doubt, $5.1M cash to Feb 2026

Filed July 21, 2026 · Compared to S-1/A Jun 25, 2026 · ~2 min read

Offering filing cluster

Same offering
  1. S-1 May 22, 2026 Hyperliquid Strategies (PURR) selling stockholder offers 35.2M shares at $1.00/share; company receives no proceeds from secondary sale EDGAR →
  2. S-1/A Jun 16, 2026 PURR raises $586M via equity facility to buy HYPE; custodian conflict & validator risk disclosed EDGAR →
  3. S-1/A Jun 25, 2026 Hyperliquid Strategies S-1/A: Minor lock-up clarification, no material changes EDGAR →
  4. S-1/A Jul 21, 2026 This filing EDGAR →

Key Changes

  • high

    Subsequent event: The Company has evaluated subsequent events from the balance sheet date through December 16, 2025, the date at which the consolidated financial statements were available to be issued. As discussed in Note 1, on Decemb…

    Notes: Subsequent Events verify on EDGAR →
  • high

    Sonnet BioTherapeutics disclosed as going concern with $5.1M cash projected to fund operations only into February 2026, requiring substantial additional financing for R&D. Auditor KPMG flagged recurring losses and negative cash flows since inception.

    Business: Going concern and liquidity view on EDGAR →
  • high

    Business combination closed December 2, 2025: Rorschach and Sonnet merged into HSI, trading as PURR on Nasdaq starting December 3, 2025. Rorschach's pre-merger common stock delisted; company intends to deregister and suspend reporting obligations.

    Business: Business combination closing view on EDGAR →

3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FTHM 10-Q) is open in full — no account needed.

Partner

Trade PURR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Source-verified from EDGAR · Narrative written by AI · Jul 22, 2026 · How we verify